AI and cell-free technologies transform gene synthesis

The gene synthesis industry is undergoing a structural shift driven by artificial intelligence and new manufacturing methodologies. AI models are increasingly used to computationally predict synthesis failures, generate novel regulatory elements, and design gene editors, reducing the need for iterative laboratory experimentation.

Global corporate investment in AI reached $252.3 billion in 2024, reflecting a significant trend in biotechnology. Companies such as Generate Biomedicines and Profluent are leveraging these advancements, with the former utilizing AI-driven protein therapeutic design and the latter focusing on AI-designed genome editors.

Parallel to AI integration, new cell-free assembly technologies are addressing the limitations of traditional bacterial-based DNA construction. Traditional methods often struggle with toxic or unstable sequences that bacteria cannot maintain. Companies like Ribbon Bio are utilizing cell-free systems and proprietary algorithms to bypass these biological constraints, allowing for the creation of complex molecules without the risks of endotoxin contamination or host-cell instability.